There is provided a dose unit for cannabidiol (CBD) comprising a pouch of an and water insoluble and saliva penetrable packaging material comprising a moist formulation, the moist formulation comprising a carrier material, water and CBD.

Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.

The present invention relates to non-toxic consumable compositions and formulations comprising chelator and base having synergistic effects on microbial metabolism and/or growth and/or pathogenic effectors and their use to promote and maintain health in mammals. The current invention also relates to non-toxic consumable compositions comprising more than one chelator and/or more than one base. The present invention further relates to methods for selecting said chelator and base composition and methods for detecting conditions in which selected compositions may be used. The present invention relates to the synergistic compositions and methods of their use for maintaining health, promoting health and treating diseases.

The present disclosure relates to mucoadhesive preparation comprising chitosan, and methods thereof. Further, the present disclosure relates to applications of the mucoadhesive preparation.

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

A dental device that provides for the entirely non-surgical management of early, cavitated dental lesions consisting of a ceramic wafer sized to cover the dental lesion and resin bonded to the tooth effectively encapsulating the dental lesion. The ceramic wafer may incorporate antimicrobial preparations, radiopaque markers, and/or silver diamine fluoride.

A self-film-forming composition in powder form, a reconstituted formula and a kit for oral use are provided, which allow an adequate colonization of the probiotic in the oral cavities together with a sufficient residence time to allow beneficial effects against the pathogens related with oral conditions. Thus, the items provided are useful for the prevention and/or treatment of a condition related to alterations of the oral microbiota, and specifically for peri-implantitis. The self-film-forming composition in powder form comprises at least a gelifier agent and/or at least a bioadhesive agent, and at least one lactic acid bacteria strain.

A pharmaceutical composition for treating oral ulcer, a preparation method and an application thereof are provided, which belong to the technical field of pharmaceutical compositions. The pharmaceutical composition includes the following raw materials: 20-50 parts of Sanhuang mixture, 15-20 parts of lotus root powder, 30-50 parts of Galla chinensis, 10-20 parts of Lonicera japonica Thunb., 10-20 parts of vanilla bean, 10-20 parts of propolis, 5-8 parts of oak bark, 5-10 parts of tea, 3-5 parts of Asarum, 1-2 parts of Atractylodes macrocephala and 5-30 parts of chlorhexidine acetate. The pharmaceutical composition for treating oral ulcer has the efficacies of clearing away heat, detoxifying removing blood stasis and reducing swelling, promoting granulation and relieving pain, inhibiting bacteria and killing bacteria, and has the advantages of quick response, easy finding of raw materials and low cost, and has a good therapeutic effect for treating oral ulcer clinically.

Pharmaceutical compositions and methods of treatment or prevention of diseases and conditions associated with or characterized by at least one of xerostomia and periodontal disease by modulation of the nitric oxide synthase pathway are provided, as are animal models and drug screening methods. Such modulation may be achieved by the administration of tetrahydrobiopterin (BH.sub.4) or its prodrugs and/or salts. Treating and preventing xerostomia can have the downstream effect of also preventing periodontitis, dental caries, parotid gland enlargement, inflammation and fissuring of the lips (chelitis), inflammation or ulcers of the tongue and buccal mucosa, oral candidiasis, salivary gland infection (sialadenitis), halitosis, and cracking and fissuring of oral mucosa.

A pharmaceutical formulation for topical dental administration or medical (e.g., implant) treatment, including effective amounts of: at least one antimicrobial compound; at least one peroxide source compound; and at least one gel agent. Also disclosed are methods of oral anatomy treatment. The pharmaceutical formulation and treatment methods provide the patient with oral anatomy benefits including, for example, decreased or arrested gum recession; decreased or arrested bone recession; decreased or arrested bone mass loss; decreased or eliminated pain; decreased or eliminated bleeding; decreased or eliminated swelling; enhanced regeneration of bone; enhanced soft tissue repair; or a combination thereof.